The healing effect of Wharton's jelly stem cells seeded on biological scaffold in chronic skin ulcers: A randomized clinical trial

Hashemi, Seyedeh‐Sara; Mohammadi, Abdorreza; Kabiri, Hamed; Hashempoor, Mohammad Reza; Mahmoodi, Mahdokht; Amini, Masoud; Mehrabani, Davood

doi:10.1111/jocd.12931

Cited by 71 publications

(63 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…are in agreement with other small sample studies, which indicate the importance of using cell therapy associated with PRP or fibrin glue to accelerate cutaneous healing. 27,[29][30][31][32] The direct correlation of the increase in the number of MSCs and the healing rate in chronic cutaneous ulcers ( Figure 6) is consistent with the results obtained by…”

Section: Discussionsupporting

confidence: 89%

A topical cell therapy approach for diabetic chronic ulcers: Effects of mesenchymal stromal cells associated with platelet‐rich plasma

Stessuk

Ribeiro-Paes

Colpas

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Diabetic cutaneous ulcers are subjected to several physiological and biochemical defects, which contribute to wound chronicity and therapeutic failure. Platelet‐rich plasma (PRP) has been used for stimulating tissue regeneration, and mesenchymal stromal cells (MSCs) have demonstrated therapeutic properties in all phases of skin regeneration in cell therapy studies. Aims The objective of this study was to evaluate the therapeutic effects related to the use of a biomembrane composed of autologous MSCs and PRP on chronic wounds of diabetic patients (pre‐post pilot study). Patients/Methods Six diabetic patients with chronic wounds for more than 6 months were subjected to adipose tissue collection for isolation of MSCs, blood collection for PRP preparation, and topical administration of a biomembrane of MSCs and PRP on each chronic wound. The statistical difference regarding the evolution of ulcers was calculated by means of paired t test. Results There was granulation tissue formation starting from 7 days after topical application. Total re‐epithelialization occurred in 5 of the 9 lesions treated, and the mean wound healing rate (WHR) was 74.55% (±32.55%) after 90 days. No cicatricial hypertrophy or retraction was observed. Conclusion Mesenchymal stromal cells topical therapy associated with PRP is well‐tolerated and able to provide a reduction in ulcer area of diabetic chronic wounds.

show abstract

Section: Discussionsupporting

confidence: 89%

A topical cell therapy approach for diabetic chronic ulcers: Effects of mesenchymal stromal cells associated with platelet‐rich plasma

Stessuk

Ribeiro-Paes

Colpas

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…Characteristic cell surface markers include CD105, CD73, and CD90. UMSCs secrete growth factors for wound healing and are capable of differentiating into fibroblast, epithelial, and endothelial cell subtypes for improved wound healing[ 37 ].…”

Section: Resultsmentioning

confidence: 99%

“…UMSCs have been employed in the treatment of chronic diabetic ulcers and significantly decrease both ulcer size and time required for wound healing to occur[ 37 ]. When seeded on an acellular amniotic membrane scaffold, UMSCs promote tissue regeneration and improve wound healing outcomes.…”

Section: Resultsmentioning

confidence: 99%

Role of stem cell therapies in treating chronic wounds: A systematic review

Raghuram¹,

Yu²,

Lo³

et al. 2020

WJSC

View full text Add to dashboard Cite

BACKGROUND The impairment of cutaneous wound healing results in chronic, non-healing wounds that are caused by altered wound environment oxygenation, tissue injury, and permissive microbial growth. Current modalities for the treatment of these wounds inadequately address the complex changes involved in chronic wound pathogenesis. Consequently, stem cell therapies have emerged as a potential therapeutic modality to promote cutaneous regeneration through trophic and paracrine activity. AIM To investigate current literature regarding use of stem cell therapies for the clinical treatment of chronic, non-healing wounds. METHODS PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus were queried with combinations of the search terms “mesenchymal stem cells,” “adult stem cells,” “embryonic stem cells,” “erythroid precursor cells,” “stem cell therapies,” and “chronic wounds” in order to find relevant articles published between the years of 2000 and 2019 to review a 20-year experience. Reference lists from the articles were reviewed to identify additional pertinent articles. Retrieved manuscripts (reviews, case reports/series, retrospective/prospective studies, and clinical trials) were evaluated by the authors for their depiction of clinical stem cell therapy use. Data were extracted from the articles using a standardized collection tool. RESULTS A total of 43 articles describing the use of stem cell therapies for the treatment of chronic wounds were included in this review. While stem cell therapies have been explored in in vitro and in vivo applications in the past, recent efforts are geared towards assessing their clinical role. A review of the literature revealed that adipose-derived stem cells, bone marrow-derived stem cells, bone marrow-derived mononuclear cells, epidermally-derived mesenchymal stem cells, fibroblast stem cells, keratinocyte stem cells, placental mesenchymal stem cells, and umbilical cord mesenchymal stem cells have all been employed in the treatment of chronic wounds of various etiologies. Most recently, embryonic stem cells have emerged as a novel stem cell therapy with the capacity for multifaceted germ cell layer differentiation. With the capacity for self-renewal and differentiation, stem cells can enrich existing cell populations in chronic wounds in order to overcome barriers impeding the progression of wound healing. Further, stem cell therapies can be utilized to augment cell engraftment, signaling and activity, and resultant patient outcomes. CONCLUSION Assessing observed clinical outcomes, potential for stem cell use, and relevant therapeutic challenges allows wound care stakeholders to make informed decisions regarding optimal treatment approaches for their patients’ chronic wounds.

show abstract

“…One of the most recent trials concerning UC-MSCs utilization in tissue regeneration regarded MSCs derived from Wharton's jelly in chronic skin ulcer treatment [43]. The authors seeded the stem cells on the acellular amniotic membrane and covered with it the wounds of five patients with chronic diabetic wounds for 9 days, with a 1-month follow-up.…”

Section: The Possible Application Of Umbilical Cord Stem Cellsmentioning

confidence: 99%

“…The authors seeded the stem cells on the acellular amniotic membrane and covered with it the wounds of five patients with chronic diabetic wounds for 9 days, with a 1-month follow-up. As a result, the wound healing time and the size of the wound were significantly decreased and some patients reported a decline in pain, probably due to anti-inflammatory, immunomodulatory and angiogenic properties of MSCs [43].…”

Section: The Possible Application Of Umbilical Cord Stem Cellsmentioning

confidence: 99%

Human umbilical cord stem cells – the discovery, history and possible application

Stefańska

Bryl

Hutchings

et al. 2020

Medical Journal of Cell Biology

View full text Add to dashboard Cite

Stem cells are now one of the most extensively studied fields in experimental medicine. Although embryonic stem cells (ESCs) have the capability to differentiate into lineages derived from all three primary germ layers, their use remains ethically controversial. Mesenchymal stromal cells’ (MSCs) utilization is not burdened with such concerns. MSCs were primarily characterized as fibroblastic cells from bone marrow stroma, with the ability to adhere to plastic and form clonogenic colonies (CFU-Fs – colony-forming unit-fibroblasts). Subsequent studies led to their isolation from various other adult or perinatal tissues, including the umbilical cord. Although in most cases MSCs are obtained from umbilical cords’ stroma (Wharton’s jelly), it has been demonstrated that both cord’s lining and endothelial layer of umbilical vein possess the cells that fulfill the minimal criteria for MSCs published in 2006 by the International Society for Cellular Therapy. Since the initial discovery, a number of pre-clinical and clinical studies were conducted with the use of MSCs derived from umbilical cords, targeting diseases such as cancer or autoimmune diseases. Moreover, their secretome may be even more beneficial, providing an opportunity to create cell-free therapies.Running title: The history of human umbilical cord stem cells

show abstract

The healing effect of Wharton's jelly stem cells seeded on biological scaffold in chronic skin ulcers: A randomized clinical trial

Cited by 71 publications

References 28 publications

A topical cell therapy approach for diabetic chronic ulcers: Effects of mesenchymal stromal cells associated with platelet‐rich plasma

A topical cell therapy approach for diabetic chronic ulcers: Effects of mesenchymal stromal cells associated with platelet‐rich plasma

Role of stem cell therapies in treating chronic wounds: A systematic review

Human umbilical cord stem cells – the discovery, history and possible application

Contact Info

Product

Resources

About